Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
Completed
Hvidovre University Hospital
Phase 2/Phase 3
2009-10-01
The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on
insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients
with type 1 diabetes.
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
Completed
Eli Lilly and Company
Phase 3
2010-01-01
No head to head comparisons between exenatide once weekly and liraglutide have been
performed. Therefore, the purpose of this study is to compare exenatide once weekly to
once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and
other clinical benefits. The study includes a 26-week treatment period and a safety follow-up
visit 10 weeks after the final study drug dose.
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
Completed
AstraZeneca
Phase 3
2010-01-01
No head to head comparisons between exenatide once weekly and liraglutide have been
performed. Therefore, the purpose of this study is to compare exenatide once weekly to
once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and
other clinical benefits. The study includes a 26-week treatment period and a safety follow-up
visit 10 weeks after the final study drug dose.
Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes
Completed
Novo Nordisk A/S
2010-09-01
This observational study is conducted in Europe. The aim of this non-interventional
(observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the
conditions of use of Victoza® in daily medical practice in France.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
